HUP0201088A2 - Új alfa-aminosav-szulfonil-vegyületek, eljárás előállításukra és ilyen vegyületeket tartalmazó gyógyászati készítmények - Google Patents
Új alfa-aminosav-szulfonil-vegyületek, eljárás előállításukra és ilyen vegyületeket tartalmazó gyógyászati készítményekInfo
- Publication number
- HUP0201088A2 HUP0201088A2 HU0201088A HUP0201088A HUP0201088A2 HU P0201088 A2 HUP0201088 A2 HU P0201088A2 HU 0201088 A HU0201088 A HU 0201088A HU P0201088 A HUP0201088 A HU P0201088A HU P0201088 A2 HUP0201088 A2 HU P0201088A2
- Authority
- HU
- Hungary
- Prior art keywords
- group
- optionally substituted
- hydrogen atom
- alkyl
- compounds
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title abstract 3
- -1 alpha-amino acid sulphonyl compounds Chemical class 0.000 title abstract 2
- 235000008206 alpha-amino acids Nutrition 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 abstract 1
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 1
- 208000030507 AIDS Diseases 0.000 abstract 1
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 abstract 1
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 abstract 1
- 208000002705 Glucose Intolerance Diseases 0.000 abstract 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 125000001980 alanyl group Chemical group 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000004474 heteroalkylene group Chemical group 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000003287 optical effect Effects 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 1
- 125000005650 substituted phenylene group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/04—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/06—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D277/06—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D277/10—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Abstract
A találmány az (I) általános képletű vegyületekre, valamint optikaiizomerjeikre és e vegyületek gyógyászati szempontból elfogadhatósavval alkotott addíciós sóira vonatkozik. Az (I) képletben aszubsztituensek főbb jelentései a következők: (a) jelentése adottesetben szubsztituált öttagú, nitrogént tartalmazó heterociklus; R1jelentése hidrogénatom vagy alkil-, acil-, prolil-, alanil-,hisztidilprolil- vagy fenilalanilprolilcsoport; Ak jelentése alkilén-vagy heteroalkilénlánc; X jelentése egyszeres kötés, vagy adottesetben szubsztituált feniléncsoport; R2 jelentése adott esetbenszubsztituált alkilcsoport vagy 3-10 szénatomos cikloalkilcsoport; Yjelentése -NR3-, (b), (c) vagy (d) képletű csoport; ahol R3 jelentésehidrogénatom vagy alkil-, 3-7 szénatomos cikloalkil- vagy arilcsoport;R4, R5 és R6 azonosak vagy eltérők lehetnek, és jelentésükhidrogénatom vagy alkilcsoport. A találmány a fenti vegyületettartalmazó gyógyászati készítményekre is kiterjed. A találmányszerinti gyógyászati készítmények többek között a dipeptidil-peptidázIV gátlására; glükózintolerancia kezelésére; átültetett szervek ésszövetek kivetésének a megakadályozására; rák kezelésére és rákosáttételek megelőzésére; valamint AIDS kezelésére alkalmazhatók. Ó
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0104142A FR2822826B1 (fr) | 2001-03-28 | 2001-03-28 | Nouveaux derives sulfonyles d'alpha-amino-acides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
Publications (3)
Publication Number | Publication Date |
---|---|
HU0201088D0 HU0201088D0 (hu) | 2002-06-29 |
HUP0201088A2 true HUP0201088A2 (hu) | 2002-12-28 |
HUP0201088A3 HUP0201088A3 (en) | 2006-02-28 |
Family
ID=8861608
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0201088A HUP0201088A3 (en) | 2001-03-28 | 2002-03-28 | New alpha-amino acid sulphonyl compounds, a process for their preparation and pharmaceutical compositions containing them |
Country Status (24)
Country | Link |
---|---|
US (1) | US6716843B2 (hu) |
EP (1) | EP1245568B1 (hu) |
JP (1) | JP3761827B2 (hu) |
KR (1) | KR100457725B1 (hu) |
CN (1) | CN1166633C (hu) |
AR (1) | AR033620A1 (hu) |
AT (1) | ATE316080T1 (hu) |
AU (1) | AU780373B2 (hu) |
BR (1) | BR0200982A (hu) |
CA (1) | CA2379197C (hu) |
DE (1) | DE60208763T2 (hu) |
DK (1) | DK1245568T3 (hu) |
EA (1) | EA004591B1 (hu) |
ES (1) | ES2256421T3 (hu) |
FR (1) | FR2822826B1 (hu) |
HK (1) | HK1050357B (hu) |
HU (1) | HUP0201088A3 (hu) |
MX (1) | MXPA02002720A (hu) |
NO (1) | NO322895B1 (hu) |
NZ (1) | NZ518035A (hu) |
PL (1) | PL353084A1 (hu) |
PT (1) | PT1245568E (hu) |
SI (1) | SI1245568T1 (hu) |
ZA (1) | ZA200202525B (hu) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6946481B1 (en) * | 1994-08-19 | 2005-09-20 | Abbott Laboratories | Endothelin antagonists |
GB0010183D0 (en) * | 2000-04-26 | 2000-06-14 | Ferring Bv | Inhibitors of dipeptidyl peptidase IV |
EP1399433B1 (en) | 2001-06-27 | 2007-08-22 | Smithkline Beecham Corporation | Fluoropyrrolidines as dipeptidyl peptidase inhibitors |
AU2002316437A1 (en) | 2001-06-27 | 2003-03-03 | Smithkline Beecham Corporation | Pyrrolidines as dipeptidyl peptidase inhibitors |
ATE374181T1 (de) | 2001-06-27 | 2007-10-15 | Smithkline Beecham Corp | Fluorpyrrolidine als dipeptidylpeptidaseinhibitoren |
WO2003024942A1 (fr) * | 2001-09-14 | 2003-03-27 | Mitsubishi Pharma Corporation | Derive thiazolidine et son utilisation medicamenteuse |
KR20050072481A (ko) * | 2002-11-07 | 2005-07-11 | 머크 앤드 캄파니 인코포레이티드 | 당뇨병의 치료 또는 예방을 위한 디펩티딜 펩티다제억제제로서의 페닐알라닌 유도체 |
JP2006510630A (ja) * | 2002-12-04 | 2006-03-30 | メルク エンド カムパニー インコーポレーテッド | 糖尿病を治療又は予防するためのジペプチジルペプチダーゼ阻害剤としてのフェニルアラニン誘導体 |
US20040242566A1 (en) * | 2003-03-25 | 2004-12-02 | Syrrx, Inc. | Dipeptidyl peptidase inhibitors |
EP1625122A1 (en) | 2003-05-14 | 2006-02-15 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
US7678909B1 (en) | 2003-08-13 | 2010-03-16 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US7579357B2 (en) * | 2003-08-13 | 2009-08-25 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US7169926B1 (en) | 2003-08-13 | 2007-01-30 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US20050065144A1 (en) * | 2003-09-08 | 2005-03-24 | Syrrx, Inc. | Dipeptidyl peptidase inhibitors |
WO2005026148A1 (en) * | 2003-09-08 | 2005-03-24 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
KR20180050427A (ko) | 2003-11-17 | 2018-05-14 | 노파르티스 아게 | 디펩티딜 펩티다제 ⅳ 억제제의 용도 |
ES2940341T3 (es) | 2004-01-20 | 2023-05-05 | Novartis Ag | Formulación y proceso de compresión directa |
CN101618216B (zh) * | 2004-01-20 | 2012-01-04 | 诺瓦提斯公司 | 直接压片配方和方法 |
US7732446B1 (en) | 2004-03-11 | 2010-06-08 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
BRPI0418639B8 (pt) * | 2004-03-15 | 2021-05-25 | Takeda Pharmaceutical | compostos inibidores de dipeptidil peptidase, assim como composição farmacêutica contendo os mesmos |
US7687638B2 (en) * | 2004-06-04 | 2010-03-30 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
WO2006019965A2 (en) | 2004-07-16 | 2006-02-23 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
JP2008507541A (ja) * | 2004-07-23 | 2008-03-13 | ロイヤルティ,スーザン・マリー | ペプチダーゼ阻害剤 |
EP1828192B1 (en) * | 2004-12-21 | 2014-12-03 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
DOP2006000008A (es) | 2005-01-10 | 2006-08-31 | Arena Pharm Inc | Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1 |
MX2007011453A (es) * | 2005-04-22 | 2008-02-12 | Alantos Pharmaceuticals Holding Inc | Inhibidores de la dipeptidil peptidasa-iv. |
AU2006278039B2 (en) * | 2005-08-11 | 2010-10-21 | F. Hoffmann-La Roche Ag | Pharmaceutical composition comprising a DPP-lV inhibitor |
EP1760076A1 (en) | 2005-09-02 | 2007-03-07 | Ferring B.V. | FAP Inhibitors |
CN101374523B (zh) * | 2005-09-14 | 2012-04-11 | 武田药品工业株式会社 | 用于治疗糖尿病的二肽基肽酶抑制剂 |
HRP20140091T4 (hr) * | 2005-09-14 | 2021-12-24 | Takeda Pharmaceutical Company Limited | Davanje inhibitora dipeptidil peptidaze |
PE20070622A1 (es) * | 2005-09-14 | 2007-08-22 | Takeda Pharmaceutical | Administracion de inhibidores de dipeptidil peptidasa |
TW200745080A (en) * | 2005-09-16 | 2007-12-16 | Takeda Pharmaceuticals Co | Polymorphs of tartrate salt of 2-[2-(3-(R)-amino-piperidin-1-yl)-5-fluoro-6-oxo-6H-pyrimidin-1-ylmethyl]-benzonitrile and methods of use therefor |
TW200745079A (en) * | 2005-09-16 | 2007-12-16 | Takeda Pharmaceuticals Co | Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor |
JP5122462B2 (ja) * | 2005-09-16 | 2013-01-16 | 武田薬品工業株式会社 | ジペプチジルペプチダーゼ阻害剤 |
GB0526291D0 (en) | 2005-12-23 | 2006-02-01 | Prosidion Ltd | Therapeutic method |
JP2009531456A (ja) * | 2006-03-28 | 2009-09-03 | 武田薬品工業株式会社 | (r)−3−アミノピペリジン二塩酸塩の調製 |
WO2007112347A1 (en) | 2006-03-28 | 2007-10-04 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
DK1971862T3 (da) | 2006-04-11 | 2011-02-14 | Arena Pharm Inc | Fremgangsmåder til anvendelse af GPR119-receptor til identificering af forbindelser anvendelige til øgning af knoglemasse hos en person |
PE20071221A1 (es) | 2006-04-11 | 2007-12-14 | Arena Pharm Inc | Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas |
US8324383B2 (en) | 2006-09-13 | 2012-12-04 | Takeda Pharmaceutical Company Limited | Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile |
SI2073810T1 (sl) * | 2006-09-13 | 2011-12-30 | Takeda Pharmaceutical | Uporaba 2-6(3-amino-piperidin-1-il)-3-metil-2,4-diokso-3,4-dihidro-2H-pirimidin -1-ilmetil-4-fluoro-benzonitrila za zdravljenje diabetesa, raka, avtoimunskih motenj in infekcije s HIV |
TW200838536A (en) * | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
US8093236B2 (en) | 2007-03-13 | 2012-01-10 | Takeda Pharmaceuticals Company Limited | Weekly administration of dipeptidyl peptidase inhibitors |
EP2108960A1 (en) | 2008-04-07 | 2009-10-14 | Arena Pharmaceuticals, Inc. | Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY |
CN101684088B (zh) * | 2008-09-22 | 2011-05-11 | 天津药物研究院 | 氰甲基吡咯衍生物、其制备方法和用途 |
AR077642A1 (es) | 2009-07-09 | 2011-09-14 | Arena Pharm Inc | Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo |
BR112012025592A2 (pt) | 2010-04-06 | 2019-09-24 | Arena Pharm Inc | moduladores do receptor de gpr119 e o tratamento de distúrbios relacionados com os mesmos |
PE20131371A1 (es) | 2010-09-22 | 2013-11-25 | Arena Pharm Inc | Moduladores del receptor gpr119 y el tratamiento de trastornos relacionados con este |
WO2012135570A1 (en) | 2011-04-01 | 2012-10-04 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012145361A1 (en) | 2011-04-19 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012145604A1 (en) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012145603A1 (en) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012170702A1 (en) | 2011-06-08 | 2012-12-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2013055910A1 (en) | 2011-10-12 | 2013-04-18 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2014074668A1 (en) | 2012-11-08 | 2014-05-15 | Arena Pharmaceuticals, Inc. | Modulators of gpr119 and the treatment of disorders related thereto |
WO2016144862A1 (en) | 2015-03-09 | 2016-09-15 | Intekrin Therapeutics, Inc. | Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy |
WO2018162722A1 (en) | 2017-03-09 | 2018-09-13 | Deutsches Institut Für Ernährungsforschung Potsdam-Rehbrücke | Dpp-4 inhibitors for use in treating bone fractures |
EP3606527A1 (en) | 2017-04-03 | 2020-02-12 | Coherus Biosciences, Inc. | Ppar-gamma agonist for treatment of progressive supranuclear palsy |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0490379A3 (de) * | 1990-12-13 | 1992-06-24 | BERLIN-CHEMIE Aktiengesellschaft | Diaminosäurederivate und pharmazeutische Zusammensetzungen |
IL111785A0 (en) * | 1993-12-03 | 1995-01-24 | Ferring Bv | Dp-iv inhibitors and pharmaceutical compositions containing them |
TW492957B (en) * | 1996-11-07 | 2002-07-01 | Novartis Ag | N-substituted 2-cyanopyrrolidnes |
US6110949A (en) * | 1999-06-24 | 2000-08-29 | Novartis Ag | N-(substituted glycyl)-4-cyanothiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
-
2001
- 2001-03-28 FR FR0104142A patent/FR2822826B1/fr not_active Expired - Fee Related
-
2002
- 2002-03-13 MX MXPA02002720A patent/MXPA02002720A/es active IP Right Grant
- 2002-03-26 AR ARP020101090A patent/AR033620A1/es unknown
- 2002-03-27 CN CNB021082286A patent/CN1166633C/zh not_active Expired - Fee Related
- 2002-03-27 JP JP2002087792A patent/JP3761827B2/ja not_active Expired - Fee Related
- 2002-03-27 AT AT02290755T patent/ATE316080T1/de not_active IP Right Cessation
- 2002-03-27 EP EP02290755A patent/EP1245568B1/fr not_active Expired - Lifetime
- 2002-03-27 NZ NZ518035A patent/NZ518035A/en unknown
- 2002-03-27 DK DK02290755T patent/DK1245568T3/da active
- 2002-03-27 DE DE60208763T patent/DE60208763T2/de not_active Expired - Fee Related
- 2002-03-27 BR BR0200982-0A patent/BR0200982A/pt not_active IP Right Cessation
- 2002-03-27 SI SI200230261T patent/SI1245568T1/sl unknown
- 2002-03-27 ES ES02290755T patent/ES2256421T3/es not_active Expired - Lifetime
- 2002-03-27 EA EA200200299A patent/EA004591B1/ru not_active IP Right Cessation
- 2002-03-27 PT PT02290755T patent/PT1245568E/pt unknown
- 2002-03-27 NO NO20021542A patent/NO322895B1/no unknown
- 2002-03-28 HU HU0201088A patent/HUP0201088A3/hu unknown
- 2002-03-28 KR KR10-2002-0016984A patent/KR100457725B1/ko not_active IP Right Cessation
- 2002-03-28 PL PL02353084A patent/PL353084A1/xx not_active Application Discontinuation
- 2002-03-28 AU AU29350/02A patent/AU780373B2/en not_active Ceased
- 2002-03-28 CA CA002379197A patent/CA2379197C/fr not_active Expired - Fee Related
- 2002-03-28 US US10/109,407 patent/US6716843B2/en not_active Expired - Fee Related
- 2002-03-28 ZA ZA200202525A patent/ZA200202525B/xx unknown
-
2003
- 2003-03-14 HK HK03101863.9A patent/HK1050357B/zh not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0201088A2 (hu) | Új alfa-aminosav-szulfonil-vegyületek, eljárás előállításukra és ilyen vegyületeket tartalmazó gyógyászati készítmények | |
EA200600892A1 (ru) | Новые хинолиновые производные | |
EA200100766A1 (ru) | Хинолин-2-он замещенные гетероарильные производные, используемые в качестве противоопухолевых агентов | |
HUP0402376A2 (hu) | Imidazol-4-karboxamid-származékok, előállításuk és az ezeket tartalmazó, elhízás kezelésére alkalmas gyógyszerkészítmények | |
EA200600225A1 (ru) | Производные пиперазина для лечения вич инфекций | |
EA200500018A1 (ru) | Бензконденсированные гетероариламидные производные тиенопиридинов, применяемые в качестве терапевтических агентов, фармацевтические композиции, включающие их, и способы их применения | |
HUP0201646A2 (hu) | Új alfa-aminosav vegyületek, eljárás ezek előállítására, és ezeket tartalmazó gyógyászati készítmények | |
EA200201271A1 (ru) | Ингибиторы 11-бета-гидроксистероиддегидрогеназы типа 1 | |
NO20056192L (no) | Kapaseinhibitorer og anvendelse derav | |
MA26697A1 (fr) | Composes nouveaux inhibiteurs de gsk-3 et compositions pharmaceutiques les contenant | |
AP1635A (en) | Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease. | |
NO20062101L (no) | Serinproteaseinhibitorer, spesielt hcv ns3-ns4a-protease | |
EA200500814A1 (ru) | Производные пирролопиримидина | |
HUP0303391A2 (hu) | Alifás, nitrogéntartalmú 5-tagú gyűrűs vegyületek, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
DOP2004001052A (es) | Inhibidores heterociclil amino de 11-beta-hidroxiesteroide deshidrogenasa tipo 1 | |
HUP0004529A2 (hu) | VLA-4 által mediált leukocita adhéziót gátló szulfonilezett dipeptid-származékok, ezeket tartalmazó gyógyászati készítmények, valamint alkalmazásuk | |
MA27560A1 (fr) | Nouveaux derives de fluorglycoside heterocycliques, produits pharmaceutiques contenant ces composes et leur utilisation | |
NO20050741L (no) | Ny fremgangsmate for syntesen og ny krystallinsk form av agomelatin og farmasoytiske sammensetninger inneholdende den | |
EA200500174A1 (ru) | Новые производные бензимидазола, полезные в качестве антипролиферативных агентов | |
EA200100983A1 (ru) | Производные 13-метилэритромицина | |
HUP0105073A2 (hu) | 2-Amino-piridin-származékok, ezek alkalmazása gyógyszerként és ezeket tartalmazó gyógyászati készítmények | |
HUP0302770A2 (hu) | Tripeptidil peptidáz inhibitorok, eljárás az előállítására és ezeket tartalmazó gyógyszerkészítmények | |
BR0210392A (pt) | Composto, métodos de tratar um paciente que tenha ou de prevenir um paciente de contrair uma doença ou condição e de preparar um composto, e, uso de um composto | |
EA200500095A1 (ru) | Производные 4-(7-гало-2-хино(кса-)линилокси)феноксипропионовой кислоты в качестве противоопухолевых средств | |
EA200000996A1 (ru) | Конденсированные с арилом азаполициклические соединения |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD9A | Lapse of provisional protection due to non-payment of fees |